Osteopontin Signaling in Shaping Tumor Microenvironment Conducive to Malignant Progression.
Akt
Angiogenesis
CD44
Cancer stem cells
Cancer-associated fibroblasts
Endothelial cells
Extracellular-signal-regulated kinase
Integrins
Mesenchymal stem cells
Metastasis
Osteopontin
Pericytes
Stromal cells
Tumor microenvironment
Tumor-associated macrophages
Tumor-stroma interaction
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
19
10
2021
pubmed:
20
10
2021
medline:
21
10
2021
Statut:
ppublish
Résumé
Context-dependent reciprocal crosstalk between cancer and surrounding stromal cells in the tumor microenvironment is imperative for the regulation of various hallmarks of cancer. A myriad of growth factors, chemokines, and their receptors aids in the interaction between cancer cells and tumor microenvironmental components. Osteopontin is a chemokine-like protein, overexpressed in different types of cancers. Osteopontin plays a crucial role in orchestrating dialogue between cancer and stromal cells. Osteopontin, in tumor microenvironment, is produced in tumor as well as stromal cells. Tumor-derived osteopontin regulates proliferation, migration, activation, and differentiation of different types of stromal cells. Osteopontin secreted from tumor cells regulates the generation of cancer-associated fibroblasts from resident fibroblasts and mesenchymal stem cells. Osteopontin also shapes immunosuppressive tumor microenvironment by controlling regulatory T cells and tumor-associated macrophages. Moreover, secretion of osteopontin from tumor stroma has been highly documented. Stromal cell-derived osteopontin induces epithelial-to-mesenchymal transition, angiogenesis, metastasis, and cancer stem cell enrichment. Tumor- or stroma-derived osteopontin mainly functions through binding with cell surface receptors, integrins and CD44, and activates downstream signaling events like PI-3 kinase/Akt and MAPK pathways. Presumably, disrupting the communication between the tumor cells and surrounding microenvironment by targeting osteopontin-regulated signaling using specific antibodies, small-molecule inhibitors, and chemotherapeutic agents is a novel therapeutic strategy for clinical management of cancer.
Identifiants
pubmed: 34664250
doi: 10.1007/978-3-030-73119-9_20
doi:
Substances chimiques
Osteopontin
106441-73-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
419-441Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Agnihotri R, Crawford HC, Haro H et al (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276:28261–28267
Ahmed M, Sottnik JL, Dancik GM et al (2016) An osteopontin/CD44 Axis in RhoGDI2-mediated metastasis suppression. Cancer Cell 30:432–443
Allan AL, George R, Vantyghem SA et al (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169:233–246
Bandopadhyay M, Bulbule A, Butti R et al (2014) Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 18:883–895
Bayless KJ, Davis GE (2001) Identification of dual α4β1 integrin binding sites within a 38 amino acid domain in the N-terminal thrombin fragment of human osteopontin. J Biol 276:13483–13489
Bellahcène A, Castronovo V, Ogbureke KU et al (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226
Birbrair A, Zhang T, Wang ZM et al (2014) Type-2 pericytes participate in normal and tumoral angiogenesis. Am J Physiol Cell Physiol 307:C25–C38
Butti R, Ghosh P, Totakura KV et al (2015) Role of osteopontin in tumor microenvironment: a new paradigm in cancer therapy. In: Multi-targeted approach to treatment of cancer. Adis, Cham, pp 113–125
Cao L, Fan X, Jing W et al (2015) Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget 6:6627–6640
Cao J, Li J, Sun L et al (2019) Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1. Mol Oncol 13:228–245
Castellano G, Malaponte G, Mazzarino MC et al (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14:7470–7480
Castello LM, Raineri D, Salmi L et al (2017) Osteopontin at the crossroads of inflammation and tumor progression. Mediat Inflamm 2017:4049098
Chakraborty G, Jain S, Kundu GC (2008b) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68:152–161
Chakraborty G, Jain S, Kale S et al (2008a) Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep 1:641–646
Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 18:99–115
Chen Y, Song Y, Du W et al (2019) Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 26:78
Cheng Y, Wen G, Sun Y et al (2019) Osteopontin promotes colorectal cancer cell invasion and the stem cell-like properties through the PI3K-AKT-GSK/3β-β/catenin pathway. Med Sci Monit 25:3014–3025
Christensen B, Petersen TE, Sørensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411:53–61
Clark EA, Brugge JS (1995) Integrins and signal transduction pathways: the road taken. Science 268:233–239
Courter D, Cao H, Kwok S et al (2010) The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 5:e9633
Crawford HC, Matrisian LM, Liaw L (1998) Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206–5215
Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3:301–313
Cui R, Takahashi F, Ohashi R et al (2007) Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57:302–310
da Silva ML, Caplan AI, Nardi NB (2008) In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26:2287–2299
Dai J, Peng L, Fan K et al (2009) Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28:3412–3422
Dean RA, Overall CM (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ™ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 6:611–623
Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7:1475–1482
Denhardt DT, Giachelli CM, Rittling SR (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41:723–749
Faulkner S, Jobling P, March B et al (2019) Tumor Neurobiology and the War of Nerves in Cancer. Cancer Discov 9:702–710
Fan CS, Chen WS, Chen LL et al (2017) Osteopontin-integrin engagement induces HIF-1α-TCF12-mediated endothelial-mesenchymal transition to exacerbate colorectal cancer. Oncotarget 9:4998–5015
Feitelson MA, Arzumanyan A, Kulathinal RJ et al (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol 35(Suppl):S25–S54
Feng YH, Su YC, Lin SF et al (2019) Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer. BMC Cancer 19:791
Franzén A, Heinegård D (1985) Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232:715–724
Fu X, Liu G, Halim A (2019) Mesenchymal stem cell migration and tissue repair. Cell 8:784
Fujita N, Fujita S, Okada Y et al (2010) Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci 51:790–794
Galland S, Stamenkovic I (2020) Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression. J Pathol 250:555–572
Gao YL, Xing LQ, Ren TJ et al (2016) The expression of osteopontin in breast cancer tissue and its relationship with p21ras and CD44V6 expression. Eur J Gynaecol Oncol 37:41–47
Gimba ER, Tilli TM (2013) Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331:11–17
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32:1267–1284
Green PM, Ludbrook SB, Miller DD et al (2001) Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 503:75–79
Hamilton G, Rath B, Klameth L et al (2015) Small cell lung cancer: recruitment of macrophages by circulating tumor cells. Onco Targets Ther 5:e1093277
Han Y, Li X, Zhang Y et al (2019) Mesenchymal stem cells for regenerative medicine. Cells 8:886
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322
He B, Mirza M, Weber GF (2006) An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192–2202
Hong SH, Lee HJ, Sohn EJ et al (2013) Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol Rep 65:970–979
Hsieh IS, Yang RS, Fu WM (2014) Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells. PLoS One 9:e109550
Hsu HP, Shan YS, Lai MD et al (2010) Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther 10:144–154
Inoue M, Shinohara ML (2011) Intracellular osteopontin (iOPN) and immunity. Immunol Res 49:160–172
Jalvy S, Renault MA, Leen LLS et al (2007) Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration. Cardiovasc Res 75:738–747
Junaid A, Moon MC, Harding GE et al (2007) Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol 292:C919–C926
Kale S, Raja R, Thorat D et al (2015) Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene 34:5408–5410
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598
Katagiri YU, Sleeman J, Fujii H et al (1999) CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219–226
Kawai T, Yasuchika K, Ishii T et al (2016) SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep 6:30489
Kerenidi T, Kazakou AP, Lada M et al (2016) Clinical significance of circulating osteopontin levels in patients with lung cancer and correlation with VEGF and MMP-9. Cancer Investig 34:385–392
Kim JS, Bashir MM, Werth VP (2012) Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 132:1825–1832
Klement JD, Paschall AV, Redd PS et al (2018) An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest 128:5549–5560
Kon S, Ikesue M, Kimura C et al (2008) Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J Exp Med 205:25–33
Kumar S, Patil HS, Sharma P et al (2012) Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr Mol Med 12:952–966
Le Bitoux MA, Stamenkovic I (2008) Tumor-host interactions: the role of inflammation. Histochem Cell Biol 130:1079–1090
Le QT, Sutphin PD, Raychaudhuri S et al (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67
Lee MN, Hwang HS, Oh SH et al (2018) Elevated extracellular calcium ions promote proliferation and migration of mesenchymal stem cells via increasing osteopontin expression. Exp Mol Med 50:1–16
Lenga Y, Koh A, Perera AS et al (2008) Osteopontin expression is required for myofibroblast differentiation. Circ Res 102:319–327
Li Y, Sun BS, Pei B et al (2015) Osteopontin-expressing macrophages in non-small cell lung cancer predict survival. Ann Thorac Surg 99:1140–1148
Lin CN, Wang CJ, Chao YJ et al (2015) The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer 15:128
Lin YH, Huang CJ, Chao JR et al (2000) Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol 20:2734–2742
Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030
Liu H, Chen A, Guo F et al (2010) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295:27–37
Liu J, Xu K, Chase M et al (2012) Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J Cell Sci 125:376–386
Liu J, Liu Q, Wan Y et al (2014) Osteopontin promotes the progression of gastric cancer through the NF-κB pathway regulated by the MAPK and PI3K. Int J Oncol 45:282–290
Luckheeram RV, Zhou R, Verma AD, Xia B (2012) CD4
Lv J, Shao Q, Wang H et al (2013) Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol Med Rep 8:1580–1586
Mentor-Marcel R, Lamartiniere CA, Eltoum IA et al (2005) Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 135:989–995
Mi Z, Guo H, Wai PY et al (2006) Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27:1134–1145
Mi Z, Guo H, Russell MB, Liu Y et al (2009) RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB-231 breast cancer cells. Mol Ther 17:153–161
Mi Z, Bhattacharya SD, Kim VM et al (2011) Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32:477–487
Mizejewski GJ (1999) Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124–138
Newham P, Humphries MJ (1996) Integrin adhesion receptors: structure, function and implications for biomedicine. Mol Med Today 2:304–313
Orimo A, Gupta PB, Sgroi DC et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348
Ota D, Kanayama M, Matsui Y et al (2014) Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts. J Mol Med (Berl) 92:1271–1281
Ouyang X, Huang Y, Jin X et al (2018) Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther 11:5933–5941
Park D, Park CW, Choi Y et al (2016) A novel small-molecule PPI inhibitor targeting integrin αvβ3-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice. Biomaterials 98:131–142
Patarca R, Freeman GJ, Singh RP et al (1989) Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 170:145–161
Pazolli E, Luo X, Brehm S et al (2009) Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 69:1230–1239
Pietras A, Katz AM, Ekström EJ et al (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14:357–369
Poltavets V, Kochetkova M, Pitson SM et al (2018) The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Front Oncol 8:431
Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163
Polyak K, Haviv I, Campbell IG (2009) Co-evolution of tumor cells and their microenvironment. Trends Genet 25:30–38
Prazeres PHDM, Leonel C, Silva WN et al (2020) Ablation of sensory nerves favours melanoma progression. J Cell Mol Med 00:1–13
Qin X, Yan M, Wang X et al (2018) Cancer-associated Fibroblast-derived IL-6 Promotes Head and Neck Cancer Progression via the Osteopontin-NF-kappa B Signaling Pathway. Theranostics 8:921–940
Raja R, Kale S, Thorat D et al (2014) Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene 33:2053–2064
Ramchandani D, Weber GF (2015) Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer. Biochim Biophys Acta 1855:202–222
Rao G, Wang H, Li B et al (2013) Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res 19:785–797
Rattigan YI, Patel BB, Ackerstaff E et al (2012) Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. Exp Cell Res 318:326–335
Sangaletti S, Tripodo C, Sandri S et al (2014) Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res 74:4706–4719
Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27:2302–2309
Schulze EB, Hedley BD, Goodale D et al (2008) The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 112:243–254
Senger DR, Perruzzi CA, Papadopoulos A (1989) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291–1299
Senger DR, Ledbetter SR, Claffey KP et al (1996) Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149:293–305
Sharon Y, Raz Y, Cohen N et al (2015) Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 75:963–973
Shi Z, Mirza M, Wang B et al (2014) Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells. Cancer Lett 344:47–53
Shinohara ML, Lu L, Bu J et al (2006) Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 7:498–506
Shinohara ML, Kim HJ, Kim JH et al (2008) Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc Natl Acad Sci U S A 105:7235–7239
Smith LL, Cheung HK, Ling LE et al (1996) Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 271:28485–28491
Sonveaux P, Végran F, Schroeder T et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–3942
Spaeth EL, Labaff AM, Toole BP (2013) Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res 73:5347–5359
Sun BS, Li Y, Zhang ZF et al (2013) Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96:1943–1951
Sun Q, Zhang B, Hu Q et al (2018) The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics 8:5072–5087
Takafuji V, Forgues M, Unsworth E et al (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361–6371
Teramoto H, Castellone MD, Malek RL et al (2005) Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 24:489–501
Tuck AB, Elliott BE, Hota C et al (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033
Varner JA, Cheresh DA (1996) Integrins and cancer. Curr Opin Cell Biol 8:724–730
Vizán P, Sánchez-Tena S, Alcarraz-Vizán G et al (2009) Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30:946–952
Wang CQ, Sun HT, Gao XM et al (2016) Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res 6:1873–1889
Wang W, Li P, Li W et al (2017) Osteopontin activates mesenchymal stem cells to repair skin wound. PLoS One 12:e0185346
Warburg O (1956) On the origin of cancer cells. Science 123:309–314
Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297–308
Weber GF, Lett GS, Haubein NC (2010) Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103:861–869
Weber CE, Kothari AN, Wai PY et al (2015) Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 34:4821–4833
Wei J, Marisetty A, Schrand B et al (2019) Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest 129:137–149
Wung JK, Perry G, Kowalski A et al (2007) Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Curr Alzheimer Res 4:67–72
Xu K, Tian X, Oh SY et al (2016) The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis. Breast Cancer Res 18:14
Yang G, Zhang Y, Wu J et al (2011) Osteopontin regulates growth and migration of human nasopharyngeal cancer cells. Mol Med Rep 4:1169–1173
Yang L, Shang X, Zhao X et al (2012a) Correlation study between OPN, CD44v6, MMP-9 and distant metastasis in laryngeal squamous cell carcinoma. J Clin Otorhinolaryngol Head Neck Surg 26:989–992
Yang L, Zhao W, Zuo WS et al (2012b) Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Chin Med J 125:293–299
Yang M, Ma C, Liu S et al (2009) Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin. Immunology 128:e237–e249
Yokosaki Y, Matsuura N, Sasaki T et al (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274:36328–36334
Yokosaki Y, Tanaka K, Higashikawa F et al (2005) Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 24:418–427
Zeisberg EM, Potenta S, Xie L et al (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67:10123–10128
Zhang C, Ma K, Li WY (2019) IL-6 promotes cancer stemness and oncogenicity in U2OS and MG-63 osteosarcoma cells by upregulating the OPN-STAT3 pathway. J Cancer 10:6511–6525
Zhang R, Yang W, Li YC et al (2015) The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients. Cell Physiol Biochem 35:175–183
Zhu B, Suzuki K, Goldberg HA et al (2004) Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol 198:155–167
Zhu Y, Denhardt DT, Cao H et al (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555–6563
Zhu Y, Yang J, Xu D et al (2019) Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to the anti-PD-L1 blockade. Gut 68:1653–1666